News|Articles|November 17, 2026

Beyond efficacy: Cost and cognition guide ARPI choice in mCSPC

Listen
0:00 / 0:00

Key Takeaways

  • In mCSPC, ARPI selection has shifted from efficacy differentiation to patient-centered tradeoffs including fatigue, cognition, monitoring burden, DDIs, dosing frequency, and payer-driven access constraints.
  • Abiraterone’s prednisone requirement and laboratory monitoring can be problematic in diabetes or cardiac disease, yet it may remain preferred when affordability dominates decision-making.
SHOW MORE

Moderators in 4 forums reviewed ARANOTE, ARACOG, and ARASEC data and discussed what differentiates doublet options in mCSPC.

Every androgen receptor pathway inhibitor (ARPI) approved for metastatic castration-sensitive prostate cancer (mCSPC) has improved outcomes when added to androgen deprivation therapy (ADT), but none has been compared directly with another. With doublet therapy now the expected standard, selection increasingly turns on tolerability, drug-drug interactions (DDIs), cost and access, and what each patient values most.

Those factors framed 4 Urology Times Clinical Forum events. The forums were moderated by Marijo Bilusic, MD, PhD, of the University of Miami, in Hollywood, Florida; John H. Bishay, MD, of UroHealth Partners, in Lincoln, Nebraska; Eric J. Giesler, MD, of Urology Austin, in Austin, Texas; and Timothy Richardson, PA-C, of AMP Urology, in a virtual format.

Bilusic noted that without head-to-head trials, no ARPI can be called more effective than another. Participants in Hollywood and Austin described the laboratory monitoring and prednisone required with abiraterone acetate (Zytiga) as a barrier in patients with diabetes or cardiac disease, whereas virtual forum participants said it remains a frequent choice when cost decides. Polling showed variation: most respondents in Lincoln and the virtual forum named darolutamide (Nubeqa) as their preferred ARPI, while most in Austin chose apalutamide (Erleada).

Asked what differentiates options once efficacy differences narrow, respondents in Austin and the virtual forum most often chose cost and accessibility. Asked which real-world outcome matters most, respondents at several forums chose quality of life over overall survival. An Austin participant said patients ask less about dosing than about cost and how a drug will make them feel.

The data review centered on ARANOTE (NCT04736199), which evaluated darolutamide plus ADT vs placebo plus ADT.1 In a health-related quality-of-life analysis, darolutamide was associated with longer time to pain progression (HR, 0.72; 95% CI, 0.54-0.96) and to deterioration in FACT-P total score (HR, 0.76; 95% CI, 0.61-0.94).2 Subgroup analyses showed consistent efficacy across age groups and among patients with 5 or more comorbidities or concomitant medications.

Bishay said the finding that adding a second agent did not worsen quality of life vs ADT alone helps when patients ask why they need 2 drugs. He added that patients who had severe fatigue on one ARPI can be reluctant to try another. Participants in the virtual forum said they weigh frailty and functional status more than chronological age.

The phase 2 ARACOG trial (NCT04335682) randomly assigned patients with advanced prostate cancer to darolutamide or enzalutamide (Xtandi) and assessed cognition with computerized CANTAB testing.3 At 24 weeks, the median change in maximally changed cognitive domain was -15.8 with darolutamide vs -36.1 with enzalutamide (P = .009).

A medical oncologist participant in Austin said cognition is discussed less than other effects because no laboratory test measures it. Giesler said he now asks partners 2 questions: whether the patient misplaces items such as keys, and whether he loses track when retelling a story. Bishay noted the trial's small size, and CANTAB modules are research tools rather than clinical diagnostics.

ARASEC (NCT05059236) compared prospectively enrolled US patients receiving darolutamide plus ADT with a propensity score-matched ADT-alone cohort from CHAARTED (NCT00309985).4 The combination was associated with improved progression-free survival (HR, 0.29; 95% CI, 0.20-0.40) and overall survival (HR, 0.50; 95% CI, 0.30-0.82). Bishay said he would have liked race included among the matching variables, and a participant in Lincoln cautioned that matching across eras can leave unmeasured differences.

When a Hollywood participant asked why clinicians who accept these data would choose another agent, Bilusic said payer preferences, dosing frequency, and adherence still lead him to prescribe different ARPIs for different patients.

Participants described pharmacists, nurse navigators, and electronic health record alerts as the main safeguards against DDIs, most often involving statins, anticoagulants, and antiplatelet agents. Virtual forum participants noted that specialty pharmacies may not see a patient's full medication list. In Hollywood, a urologist participant urged closer collaboration with medical oncology, including referral for sexual health concerns that patients may not raise on their own.

Each forum closed with the case of a 68-year-old man with coronary artery disease, diabetes, and metachronous bone metastases who wanted to remain active. In Austin, one participant ruled out enzalutamide because of fatigue and abiraterone because of diabetes, whereas a medical oncologist participant said he uses apalutamide or darolutamide, citing overall survival data for the former and quality-of-life data for the latter. Participants there agreed that the patient defines what thriving means.

With several effective doublets available, the decision in mCSPC has shifted from whether to intensify to which agent fits the patient. That choice depends on a team able to reconcile medications, navigate cost, and keep asking about function and cognition over years of therapy.

REFERENCES

1. Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42(36):4271-4281. doi:10.1200/JCO-24-01798

2. Morgans A, Haresh KP, Jievaltas M, et al. Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. J Clin Oncol. 2025;43(suppl 17):5004. doi:10.1200/JCO.2025.43.16_suppl.5004

3. Morgans A, Bobek O, Kwon DH, et al. Cognitive effects of darolutamide vs enzalutamide: results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology. J Clin Oncol. 2026 (suppl 16; abstr 5005). doi:10.1200/JCO.2026.44.16_suppl.5005

4. McKay R, et al. ARASEC: A novel pragmatic trial design comparing darolutamide plus ADT versus ADT in US patients with metastatic hormone-sensitive prostate cancer using propensity score matching with an external phase 3 trial control arm. J Urol. 2025;213(5S). doi:10.1097/01.JU.0001109788.ARASEC


Related to this article